Provided by Tiger Trade Technology Pte. Ltd.

AbCellera Biologics

13.74
-0.1700-1.22%
Post-market: 13.740.00000.00%16:10 EDT
Volume:3.69M
Turnover:51.30M
Market Cap:4.45B
PE:-25.19
High:14.30
Open:14.10
Low:13.66
Close:13.91
52wk High:15.02
52wk Low:2.75
Shares:324.00M
Float Shares:221.00M
Volume Ratio:0.56
T/O Rate:1.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5455
EPS(LYR):-0.4902
ROE:-17.30%
ROA:-10.39%
PB:4.97
PE(LYR):-28.03

Loading ...

Stock Track | AbCellera Biologics Plunges 5.47% in Pre-Market Amid Concerns Over Continued Losses and Rising R&D Expenses Despite Q1 Beat

Stock Track
·
May 12

Analysts Offer Insights on Healthcare Companies: Ceribell, Inc. (CBLL) and AbCellera Biologics (ABCL)

TIPRANKS
·
May 12

Stock Track | AbCellera Biologics Plunges 7.24% Post-Market Despite Q1 Beat as Investors Focus on Continued Losses and Rising R&D Expenses

Stock Track
·
May 12

AbCellera Biologics options imply 9.7% move in share price post-earnings

TIPRANKS
·
May 12

Stock Track | AbCellera Biologics Plunges 6.48% After-Hours Despite Beating Q1 Estimates

Stock Track
·
May 12

Stock Track | AbCellera Biologics Soars 7.62% After-Hours on Earnings Beat and Positive Clinical Data

Stock Track
·
May 12

Earnings Flash (ABCL) AbCellera Biologics Posts Q1 Per Share Loss of $0.14, vs. FactSet Est Loss $0.17

MT Newswires Live
·
May 12

AbCellera Biologics Q1 Loss Narrows, Revenue Rises

MT Newswires Live
·
May 12

Abcellera Biologics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

AbCellera Q1 revenue more than doubles, beats estimates

Reuters
·
May 12

AbCellera Q1 FY26 net loss narrows to $43.2 million; revenue rises to $8.3 million

Reuters
·
May 12

AbCellera Biologics Q1 EPS $(0.14) Beats $(0.20) Estimate, Sales $8.315M Beat $5.856M Estimate

Benzinga Earnings
·
May 12

BRIEF-AbCellera Q1 Revenue USD 8.3 Million Vs. IBES Estimate USD 5.86 Million

Reuters
·
May 12

Abcellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for Abcl635

THOMSON REUTERS
·
May 12

Press Release: AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

Dow Jones
·
May 12

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 11

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 08

AbCellera to present at Bank of America Health Care Conference

Reuters
·
May 08

AbCellera Biologics Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
May 06

Cantor Fitzgerald Initiates AbCellera Biologics at Overweight With $7 Price Target

MT Newswires Live
·
May 05